Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

This study found that in young men with post-finasteride syndrome, there are potential genetic risk factors associated with psychological and sexual dysfunctions, suggesting genetic screening may be beneficial before prescribing finasteride.

This review reports that hyperandrogenic conditions in women, which affect skin and overall well-being, lack dedicated treatment guidelines, presenting challenges in standardizing care.

This study assessed outcomes and complications of upper-face feminization surgery among 20 transgender patients, highlighting that insufficient browbone reduction was a common issue in prior surgeries, and emphasizing meticulous planning to prevent revisions and dissatisfaction.

Women with hyperandrogenism, especially those with PCOS, are more likely to have psychiatric disorders.

This study reported that testosterone levels over 150 ng/dL combined with lack of testosterone suppression during a low-dose dexamethasone suppression test may indicate androgen-producing tumors, though this wasn't consistent across all cases.

This study presents a new survey instrument that was cognitively tested for understanding menstrual cycle characteristics and androgen excess, including hirsutism, alopecia, and acne.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

This review outlines the challenges in diagnosing hyperandrogenism in women, focusing on its manifestations like hirsutism, acne, and virilization, but provides no new results.

This case report describes a 23-year-old woman with a history of ambiguous genitalia and complex medical conditions, including a pelvic mass and hirsutism, observed from childhood to adulthood.

This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.

In this study, self-esteem, body image, and sexual function in women significantly improved after total laser pubic hair removal.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

This review highlights that current diagnostic and treatment methods for chronic pelvic pain syndrome lack robust evidence, suggesting a need for further research.

This review discusses various aspects of Impulse Control Disorders, but reports no new clinical findings; the authors highlight existing knowledge gaps and the need for proven treatments.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

This study found that signs of potential adverse events varied based on demographic and health factors in a large cohort, suggesting the need for more inclusive evaluations to better understand these differences at a population level.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

In this narrative review, the authors discuss the potential impact of hormone therapy on androgenetic alopecia among transgender individuals, especially transgender men using testosterone, and its adverse effects on emotional well-being and body image within a socially stigmatized population.

This review discusses various cutaneous side effects potentially linked to oral contraceptive use but provides no new clinical results, emphasizing the need for more evidence in certain associations.

The case showed the need for quick investigation of virilization in women and how emotional health is linked to physical health.

This case report describes a rare instance of Satoyoshi syndrome in a 27-year-old Asian American woman, notable for her normal ovarian function despite typical syndrome features.

Finasteride treatment for hair loss can cause erectile dysfunction.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

This study reports two cases of myasthenia gravis patients with thymoma who exhibited various autoimmune symptoms including alopecia, suggesting a link between thymus-related immune dysregulation and comorbid conditions.

This case study reports on a 44-year-old male exhibiting persistent neuropsychiatric symptoms described as Post-Finasteride Syndrome after discontinuing long-term finasteride use, highlighting the ongoing debate regarding its classification as a true disease process.

This study assessed clinical patterns of skin and mucosal symptoms in postmenopausal women, finding that a significant number experienced conditions like atrophic vaginitis, oral complaints, and hair loss, often without realizing their menopausal link.

This article discusses sexual interests and behavior in individuals with Prader-Willi syndrome and notes the lack of prior descriptions in this area, but reports no new clinical results.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.